title: Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells.
abstract: Adenosine is an important signaling molecule that regulates multiple physiologic processes and exerts major anti-inflammatory actions. Tumors have high concentrations of adenosine, which could inhibit the function of tumor-infiltrating lymphoid cells. We investigated the ability of adenosine and its stable analogue 2-chloroadenosine (CADO) to inhibit cytokine production and cytotoxic activity of lymphokine-activated killer (LAK) cells and determined whether both these effects are initiated via a common pathway. CADO strongly inhibited cytotoxic activity of LAK cells and attenuated the production of IFN-gamma, granulocyte macrophage colony-stimulating factor, tumor necrosis factor alpha, and macrophage inflammatory protein-1alpha by LAK cells stimulated by cross-linking of the Ly49D receptor. These inhibitory effects were associated with the ability of CADO to stimulate cyclic AMP (cAMP) production and activate protein kinase A (PKA). Using cAMP analogues with different affinities for the A and B sites of the regulatory subunits of PKA types I and II, we found that activation of PKA I, but not PKA II, mimicked the inhibitory effects of CADO on LAK cell cytotoxic activity and cytokine production. Inhibitors of the PKA catalytic subunits (H89 and PKI(14-22) peptide) failed to abrogate the inhibitory effects of CADO whereas Rp-8-Br-cAMPS, an antagonist of the RI subunit, blocked the inhibitory effects of CADO. We conclude that the inhibitory effects of adenosine are probably mediated via cAMP-dependent activation of the RI subunits of PKA I but are independent of the catalytic activity of PKA. Tumor-produced adenosine could be a potent tumor microenvironmental factor inhibiting the functional activity of tumor-infiltrating immune cells.
authors.affiliation: Department of Pathology and University of Pittsburgh Cancer Institute, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Lokshin
authors.forename: Tatiana
authors.initials: T
authors.lastname: Raskovalova
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Huang
authors.forename: Lefteris C
authors.initials: LC
authors.lastname: Zacharia
authors.forename: Edwin K
authors.initials: EK
authors.lastname: Jackson
authors.forename: Elieser
authors.initials: E
authors.lastname: Gorelik
mesh_terms: D015762:2-Chloroadenosine / Q000494:pharmacology*; D000241:Adenosine / Q000494:pharmacology*; D000818:Animals; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000276:immunology; D004789:Enzyme Activation; D005260:Female; D007527:Isoenzymes; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects* / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL
chemical_list: D016207:Cytokines; D007527:Isoenzymes; D015762:2-Chloroadenosine; D017868:Cyclic AMP-Dependent Protein Kinases; D000241:Adenosine